For patients with unresectable or metastatic melanoma, recently emerged novel systemic treatment modalities such as Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programed Death-1 (PD-1)/PD-L1 blockade as well as BRAF and MEK inhibition have expanded the spectrum of therapeutic options (2–13). Here, BRAF is linked to metastatic melanoma.